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Introduction: The presence of a new autoantibody system, anti-carbamylated protein (anti-CarP) antibodies, has
been identified in rheumatoid arthritis (RA). The presence of anti-CarP antibodies was evaluated in samples taken
from individuals who subsequently developed RA before and after onset of symptoms and related to previously
analysed antibodies against citrullinated peptides (ACPA specificities) and anti-CCP2.
Methods: A total of 252 individuals, with 423 samples from before onset of symptoms of RA, and 197 population
controls were identified as donors to the Medical Biobank of Northern Sweden; 192 of them were also sampled at
the time of diagnosis. All samples were analysed for anti-CarP IgG and anti-CCP2 antibodies using ELISAs. Ten different
antibody reactivities against citrullinated antigens (ACPA specificities) were analysed using a custom-made microarray
based on the ImmunoCAP ISAC system (Phadia).
Results: The concentration of anti-CarP antibodies was significantly increased in the pre-symptomatic individuals
compared with controls (P <0.001) and also increased significantly after disease onset (P <0.001). The sensitivity
for anti-CarP antibodies in the pre-symptomatic individuals was 13.9% (95% CI: 11 to 17.6) and 42.2% (95% CI:
35.4 to 49.3) following development of RA. Anti-CarP antibody positivity was found in 5.1% to 13.3% of individuals
negative for anti-CCP2 or ACPA specificities. Presence of anti-CarP antibodies was significantly related to radiological
destruction at baseline, at 24 months and also to radiological change (P <0.05, all).
Conclusions: The results indicate that anti-CarP antibodies are associated with disease development, even after
adjusting for the presence of different ACPA fine specificities, and in anti-CCP2 negative individuals and contribute to
the identification of a subset of patients with worse radiological progression of the disease independent of ACPA.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by inflammation within the joints that
eventually leads to the destruction of cartilage and bone.
However, the aetiopathogenesis of this disease is not yet
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stated.associated with the disease, for example, rheumatoid fac-
tor (RF), anti-citrullinated protein antibodies (ACPA)
and the recently described antibodies directed against
carbamylated proteins (anti-CarP antibodies) [1].
The citrullinated proteins recognized by ACPA arise
due to the deimination of an arginine residue into citrul-
line by an enzyme, peptidyl arginine deaminase (PAD)
[2]. We and others have shown that the presence of anti-
bodies against citrullinated proteins/peptides (ACPA)
measured as anti-CCP antibodies of immunoglobulinhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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development of RA by a number of years [3-6]. More re-
cently, we have also shown that an increasing number of
ACPA specificities can be detected the closer the sam-
ples were collected before the onset of RA [7]. The
ACPA specificities were initially restricted and without
any obvious epitope profile, but over time expanded with
epitope spreading and involved more specific responses,
especially with regard to antibody reactivities against α-
enolase (CEP-1/Eno5-21), fibrinogen (Fib)β36-52, and
filaggrin (CCP-1/Fil307-324), when approaching the on-
set of symptoms [7,8]. The presence of ACPA in RA-
patients has also been shown to predict a more severe
disease [9-11].
In addition to deimination, another post-translational
modification of proteins is carbamylation where prefer-
entially lysines are converted to homocitrulline by a
non-enzymatic process [12]. Anti-CarP antibodies have
been identified in patients with RA [13]. Furthermore,
these antibodies have been shown to be associated with
the development of RA in patients with arthralgia [14]
and were associated with a more severe disease course
in ACPA-negative patients [13]. Similar to ACPA, anti-
CarP antibodies have also been observed in individuals
before the onset of clinical symptoms of RA [15].
In this study blood samples donated to the Medical
Biobank of Northern Sweden by individuals prior to the
onset of RA and of controls derived from the same
population were analysed for anti-CarP antibodies. Al-
though the presence of anti-CarP antibodies in samples
from healthy subjects prior to clinical diagnosis of RA
has already been shown in a relatively small Dutch co-
hort [15], we were now able to analyse samples from a
larger cohort of individuals for the presence of anti-CarP
antibodies in relation to antibodies against anti-CCP2
and several ACPA specificities. Furthermore, samples
were collected before and after the onset of disease
allowing a comparison between anti-CarP antibodies
and ACPA fine-specificities with regard to their possible




A case–control study was conducted based on individ-
uals included in population surveys within the Medical
Biobank of Northern Sweden and the Maternity cohort.
The criteria for recruitment and collection and storage
of blood samples have been described previously [6]. Co-
horts included in the Medical Biobank are population
based, and all adult individuals residing in the county of
Västerbotten are continuously invited to participate. The
Maternity cohort is a collection of serum samples ob-
tained from pregnant women in northern Sweden whohad undergone screening for immunity to rubella (6).
The registers from the Medical Biobank and the Mater-
nity cohort were co-analysed with the registers of pa-
tients with RA fulfilling the 1987 American Rheumatism
Association classification criteria for RA [16] and at-
tending the Department of Rheumatology, University
Hospital in Umeå, with a known date for the onset of
symptoms to identify individuals who had donated blood
samples prior to the onset of symptoms of RA. In this
study only samples donated less than 13 years before the
onset of symptoms were included. The number of indi-
viduals identified and the procedure for excluding any
sample has previously been described in detail [7]. Con-
sequently, 252 individuals (58 men and 194 women) were
included in this study, who were referred to as ‘pre-
symptomatic individuals’ with a total of 423 (375 from
the Medical Biobank and 48 from the Maternity cohort)
blood samples at different time points. Forty-six individ-
uals had contributed with two samples, 24 three samples,
13 four, seven with five and two with six samples. The
median (interquartile range (IQR)) time pre-dating onset
of symptoms using all samples was 5.2 (6.3) years and for
the samples obtained closest to before disease onset it
was 3.5 (4.9) years. Controls (N = 197) were randomly
identified from the same cohorts within the register at
the Medical Biobank and matched for age, sex and date
of sampling. Of the pre-symptomatic individuals 192
were also sampled when they presented at the early arth-
ritis clinic (Department of Rheumatology, University
Hospital, Umeå) and were diagnosed with RA. The me-
dian (IQR) duration of symptoms before these patients
were diagnosed following the onset of symptoms was 7
(5.8) months. Radiographs of the hands and feet of pa-
tients with RA (n = 181) were available at baseline and
after 24 months; these radiographs were graded accord-
ing to the Larsen score [9] and read in chronological
order by two readers, who were blind to the antibody data.
Radiological progression was defined as the increase of the
Larsen score between baseline and 24 months, with the
smallest detectable change less than four (calculated ac-
cording to ref. [17]). All individuals were classified either as
being a ‘non-smoker’ or an ‘ever-smoker’ (past or current).
Demographic data of the cases and controls is presented in
Table 1.
The Regional Ethics Committee at the University
Hospital, Umeå, Sweden, approved this study and all par-
ticipants gave their written informed consent when donat-
ing blood samples.
Analyses of anti-CarP antibodies and anti-CCP2 antibodies
The anti-CarP antibodies were determined by ELISA as
described previously [13]. Briefly, Nunc Maxisorp plates
(Nunc, Roskilde, Denmark) were coated overnight using
carbamylated fetal calf serum (Ca-FCS) or non-modified
Table 1 Demographic data for 252 individuals with 423
samples at a median (IQR) of 5.2 (6.3) years before the








Female sex, % 84.3 77 75
Median age,
years (IQR)
50.1 (20.2) 52 (17.4)a 57.5 (14.3)
Ever smoker
n/total (%)
83/168 (49.4) 159/246 (64.6) 127/188 (67.6)
aMedian age, as calculated for all samples when collected (number = 423). IQR,
interquartile range; RA, rheumatoid arthritis.
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added and allowed to bind overnight. Binding was deter-
mined using horseradish peroxidase (HRP)-conjugated
rabbit-anti-human IgG (DAKO, Glostrup, Denmark) in
combination with ABTS (2,2′-azino-bis(3-ethylbenzo-
thiazoline-6-sulphonic acid). The investigators who car-
ried out the anti-CarP ELISA tested the samples in a
blind fashion. The cut-off level for anti-CarP antibodies
was defined as the antibody reactivity expressed as the
sum of optimal sensitivity and specificity, using receiver
operating characteristic (ROC) curves, based on the con-
centrations in samples from the patients with RA in-
cluded in this study and the controls from the Medical
Biobank. The cut-off for positivity was set at 256.07 arbi-
trary units/mL (AU/mL) giving a specificity of 97%.
Detection of anti-CCP antibodies was successfully per-
formed using ELISA according to the manufacturer’s in-
structions (Euro-Diagnostica, Malmö, Sweden). The cut
off for positivity was set at 25 AU/mL.
Multiplex assay
Serum and plasma samples were analysed for levels of
ACPA specificities of the IgG isotype using a custom-
made microarray based on the ImmunoCAP ISAC sys-
tem (ThermoFischer/Phadia, Uppsala, Sweden) of the
first version included on the platform [18]. Briefly, ten
peptides representing the four candidate autoantigens
citrullinated fibrinogen, a-enolase, vimentin and collagen
type II: fibrinogen (Fib) α563-583 (citrullinated at pos-
ition 573), Fibα580-600 (citrullinated at position 591),
Fibβ62-81a (citrullinated at position 72), Fibβ62-81b
(citrullinated at position 74), Fibβ36-52 (citrullinated at
position 44), α-enolase (CEP-1/Eno5-21) ( citrullinated
at position 10, 16), triple helical collagen type II (citC1
CII 359–369 with citrulline at 360 and 365), filaggrin
(CCP-1/Fil307-324), vimentin (Vim) 2–17 (citrullinated
at position 4, 12,13), and Vim60-75 (citrullinated at pos-
ition 64, 69, 71), were analysed as previously described
[7,18] (Additional file 1: Table S1). For all reactivities
both the citrullinated and the native arginine-containingpeptides were analysed and for all except one, citC1, the
determined delta-value was used. The exception was due
to the fact that the arginine containing citC1 is an auto-
antigen in itself [19]. The cut-off values were based on
ROC curves analysed on the RA-patients and controls.
Statistical analysis
For comparing continuous data between two groups the
Mann–Whitney U test was used and the Kruskal Wallis
test for several groups. Correlation analyses were per-
formed using Spearman’s rank correlation test (rs). Lo-
gistic regression analyses were performed to identify
associations between antibodies and disease development,
presented as odds ratios (ORs) and 95% confidence inter-
vals (95% CIs). Univariate analyses of variance were used
to identify associations between factors and continuous
data. Relationships between categorical data (positive ver-
sus negative) were compared using chi-square analysis or
Fisher’s exact test as appropriate. Considering the study to
be explorative, P values less than or equal to 0.05 were
considered significant.
Statistical calculations were performed using SPSS for
Windows, version 22. Sensitivity, specificity, odds ratios
(ORs) and 95% confidence intervals (CIs) were calcu-
lated with the XLSTAT program (version 2014.1.04) in
Microsoft Excel 2013 (Addinsoft).
Results
Levels of anti-CarP antibodies in pre-symptomatic
individuals, patients and controls
The levels of anti-CarP antibodies in the pre-symptomatic
individuals were significantly increased compared with that
of controls, namely, a median (IQR) of 44 (142) AU/mL
and 8 (43) AU/mL, respectively (P <0.0001). Levels for the
sample in each individual closest to onset of symptoms are
presented in Figure 1 (Figure 1). The concentration after
the onset of disease (median (IQR) 198 (379) AU/mL)
was significantly increased compared with that for
both the control subjects and pre-symptomatic individuals
(P <0.0001, Kruskal-Wallis) (Figure 1).
Frequency of anti-CarP antibody positivity in
pre-symptomatic individuals, patients and controls
The increased levels of anti-CarP antibodies in the pre-
symptomatic individuals are also reflected in an increased
frequency of anti-CarP positive individuals. The frequency
of samples with anti-CarP antibodies was 13.9% (95% CI
11.0% to 17.6%) when all samples were included in the
analysis, and the frequency of being ever positive for the
antibody before onset of symptoms was 18.3% (95% CI
14.0% to 23.5%) and in the RA patients was 42.2% (95% CI
35.4% to 49.3%). The frequency of samples with positive
anti-CarP antibody detection was higher the closer in time
to onset of symptoms, for example, 21.8% (95% CI 14% to
Figure 1 Concentrations of anti-CarP antibodies in pre-symptomatic individuals closest to symptom onset (median (IQR) 3.5 (4.9) years)
and in controls and patients with RA. Anti-CarP, antibodies against carbamylated protein; IQR, interquartile range; RA, rheumatoid arthritis.
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antibodies above the cut-off value less than two years be-
fore the onset of symptoms and 18.6% (95% CI 12.8% to
26.3) when analysed at less than three years before disease
onset, although the gradual increase was not significant
during the pre-dating period (Figure 2). Ever being
positive for anti-CarP antibodies was associated with
the development of RA in the pre-symptomatic individuals
(OR = 7.1 95% CI 3.0 to 17.0). Adjustments for age, sex or
ever being a smoker, did not affect the association betweenFigure 2 Accumulated percentage of positivity of anti-CarP antibodie
anti-citrullinated protein antibodies; anti-CarP, antibodies against carbamylaanti-CarP antibodies and disease development (data not
shown). Furthermore, the association remained after
adjusting for each ACPA fine specificities separately but
not after adjusting for anti-CCP2 antibodies (OR = 2.4,
95% CI 0.9 to 6.7) (Table 2). However, after stratifica-
tion for anti-CCP2 antibodies, anti-CarP antibodies were
associated with disease development in anti-CCP2 negative
pre-symptomatic individuals (OR = 3.4 95% CI 1.1 to 9.8)
(data not shown). Analysis in patients with RA showed an
association between anti-CarP antibodies and the RAs, the different ACPA specificities and anti-CCP2 antibodies. ACPA,
ted proteins; anti-CCP2, anti-cyclic citrullinated peptide 2.
Table 2 The association between anti-CarP antibodies
and anti-CarP antibodies adjusted for ACPA and anti-
CCP2, respectively
Pre-symptomatic individualsa RA patientsb
Antibodies against OR 95% CI OR 95% CI
CarP 7.1 3.0-17.0 23.2 9.8-55.0
after adjustments for each antibody:
CarP 2.4 0.9-6.9 3.8 1.2-12.2
CCP2 43.8 13.54-141.9 125.0 37.4-417.7
CarP 3.4 1.35-8.8 8.1 3.02-21.4
CEP-1 10.0 4.67-21.6 31.4 14.3-69.2
CarP 4.9 2.0-12.1 16.2 6.7-39.0
citC1 5.1 2.23-11.8 19.2 7.9-46.8
CarP 4.5 1.81-11.3 9.9 3.9-25.3
Fibß36-52 6.6 3.50-12.3 17.3 8.9-33.6
CarP 6.3 2.60-15.3 20.9 8.8-49.8
Fibß62-81a(72) 6.1 2.32-16.1 4.9 1.7-14.0
CarP 4.6 1.86-11.5 17.3 7.1-42.3
Fibß62-81b(74) 37.6 5.11-277.2 79.1 10.7-586.7
CarP 5.6 2.33-13.7 14.4 6.0-35.0
Fibα563-583 3.1 1.28-7.3 7.4 3.1-17.5
CarP 6.1 2.54-14.8 21.3 8.9-50.5
Fibα580-600 1.9 0.89-4.2 2.1 0.87-4.9
CarP 3.8 1.51-9.7 15.0 6.1-36.9
Fil307-324 12.8 5.40-30.3 19.2 7.9-46.9
CarP 5.9 2.42-14.2 17.3 7.2-41.4
Vim60-75 2.5 1.22-5.2 4.0 1.9-8.5
CarP 6.2 2.58-15.1 22.0 9.26-52.3
Vim2-17 3.1 1.24-8.0 3.6 1.333-9.9
CarP 3 1.2-8.1 12.2 4.9-30.4
CCP2+ and all ACPA 7.2 4.7-11.2 9.7 5.7-16.5
aCalculated as ever being positive, n = 253; bnumber = 192. ACPA, anti-citrullinated
protein antibodies; anti-CarP, antibodies against carbamylated proteins; anti-CCP2,
anti-cyclic citrullinated peptide 2; CI, confidence interval; fib, fibrinogen; OR, odds
ratio; RA, rheumatoid arthritis; vim, vimentin.
Table 3 Frequency of positivity for anti-CarP antibodies







Number (%) Anti- CarP +
number (%)
Number (%) Anti- CarP +
number (%)
All individuals 423 (100) 59 (13.9) 188 (100) 81 (42.2)
CCP2 + 151 (35.7) 45 (29.8) 141 (74.6) 74 (52.5)
CCP2 - 272 (64.3) 14 (5.1) 48 (25.4) 5 (10.4)
CEP-1 + 116 (28) 32 (27.6) 128 (68.1) 68 (53.1)
CEP-1 - 299 (72) 24 (8.1) 60 (31.9) 11 (18.3)
CitC1 + 59 (14.2) 18 (30.5) 63 (33.5) 38 (60.3)
CitC1 - 356 (85.8) 38 (10.7) 125 (66.5) 41 (32.8)
Fibß36–52 + 101 (24.4) 24 (23.8) 122 (64.9) 66 (54.1)
Fibß36–52 - 313 (75.6) 31 (9.9) 66 (35.1) 13 (19.7)
Fibß62-81a(72)+ 38 (9.2) 5 (13.2) 28 (14.9) 16 (57.1)
Fibß62-81a(72) - 377 (90.8) 51 (13.5) 160 (85.1) 63 (39.4)
Fibß62-81b(74)+ 65 (15.7) 20 (30.8) 67 (35.6) 36 (53.7)
Fibß62-81b(74) - 350 (84.3) 36 (10.3) 121 (64.4) 43 (35.5)
Fibα580-600 + 32 (7.7) 9 (28.1) 27 (14.4) 16 (59.3)
Fibα580-600- 383 (92.3) 47 (12.3) 161 (85.6) 63 (39.1)
Fibα563-583 + 36 (8.7) 9 (25) 65 (34.6) 43 (66.2)
Fibα563-583 - 379 (91.3) 47 (12.4) 123 (65.4) 36 (29.3)
Fil307-324 + 110 (26.5) 27 (24.5) 88 (46.8) 48 (54.5)
Fil307-324 - 305 (73.5) 29 (9.5) 100 (53.2) 31 (31)
Vim 2–17 + 25 (6) 4 (16) 22 (11.7) 10 (45.5)
Vim 2–17 - 390 (94) 52 (13.3) 166 (88.3) 69 (41.6)
Vim 60–75 + 38 (9.2) 9 (23.7) 56 (29.8) 35 (62.5)
Vim 60-75- 377 (90.8) 47 (12.5) 132 (70.2) 44 (33.3)
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cluding anti-CCP2 antibodies (Table 2).
Relationships between anti-CarP antibodies and ACPA
specificities and anti-CCP2 antibodies
The presence of anti-CarP antibodies, anti-CCP2 and
several ACPA specificities was investigated in order to
describe populations of patients and pre-symptomatic
individuals with overlapping and unique antibody speci-
ficities (Table 3). Among the pre-symptomatic individ-
uals negative for any of the individual ACPA specificities
8.1% to 13.5% were positive for anti-CarP antibodies, the
lowest frequency being for anti-CEP-1 and the highest
for anti-Fibß62-81a (72). When selecting samplesnegative for all ACPA specificities irrespective of anti-
CCP2 antibodies, the frequencies of positivity for anti-
CarP antibodies were 2.8%, 5.8% and 13.3% in controls,
pre-symptomatic individuals and RA-patients, respect-
ively (for further details on the relationships to sub
specificities, see Table 3). The distribution of the combi-
nations of anti-CarP and anti-CCP2 before and after dis-
ease onset showed a relative increase of double positivity
after onset compared with the distribution before onset
where the number of double negativity dominated (Figure 3).
The relative distribution of the combinations of one anti-
body negative and the other antibody positive (anti-CarP+/
anti-CCP- and CarP-/anti-CCP+) were fairly unchanged
(Figure 3).
The concentration of anti-CarP antibodies correlated
with those of anti-CCP2 antibodies both in the pre-
symptomatic individuals and in RA patients (rs= 0.31
and 0.52, respectively, P <0.001 for both). Additionally
there were correlations between the concentrations of
anti-CarP antibodies and the different ACPA specificities
Figure 3 The relative distribution in percentage of the combinations of positivity and negativity of anti-CarP and anti-CCP2 antibodies
illustrated by pie charts. anti-CarP, antibodies against carbamylated proteins; anti-CCP2, anti-cyclic citrullinated peptide 2.
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P <0.0001 to 0.04) and RA patients (rs = 0.15 to 0.46,
P <0.0001 to 0.04) with the exception of Vim2-17 and
Fibα580-600(591) in both groups and Fibß62-81a(72)
in the pre-symptomatic individuals.
There were no significant differences between anti-
CarP antibodies or anti-CCP2 antibodies or ACPA
specificities in the predating time when the anti-
bodies were first detected positive for any of the
antibodies (data not shown). In 20 and 42 individuals
anti-CCP2 antibodies and any ACPA specificity, re-
spectively, preceded positivity for anti-CarP antibodies. In
five and two individuals anti-CarP antibody positivity pre-
ceded the presence of anti-CCP2 antibodies and any ACPA
specificity, respectively.
The presence of anti-CarP antibodies is associated with
radiological damage, especially in anti-CCP2 negative
individuals
Positivity for anti-CarP antibodies in the pre-symptomatic
individuals was associated with increased radiological
damage as detected by a higher Larsen score at baseline,
that is, when RA was diagnosed, the median (IQR) value
for the Larsen score was 9.0 (6.5) compared with 5.0 (9.0)
(P = 0.003) in anti-CarP antibody negative individuals.
This association remained after adjustment for anti-CCP2
antibodies. Anti-CarP antibodies analysed after disease on-
set were also associated with radiological progression and
outcome calculated as Larsen score at baseline in the
patients with early RA (ß = 2.15, 95% CI 0.40 to 3.90,
P = 0.017) at 24 months (ß = 4.49, 95% CI 1.67 to 7.32,
P = 0.002) and also with the radiological progression
(ß = 2.44, 95% CI 0.53 to 4.35, P = 0.013). The outcome
at 24 months remained significant after adjustment for
the Larsen score at baseline (ß = 1.89, 95% CI 0.02 to
3.75, P = 0.048). Stratification for anti-CCP2 antibodies
revealed that the association of anti-CarP antibodies
was strengthened in anti-CCP2 negative patients at base-
line (ß = 5.38, 95% CI 0.94 to 39.82, P = 0.019), after24 months (ß = 8.57, 95% CI 3.36 to 13.79, P = 0.002) and
the radiological progression (ß = 2.3.02, 95% CI 0.17 to
5.87, P = 0.038), and non-significant in anti-CCP2 posi-
tive patients. The pattern was similar when stratified
for the presence or absence of the triplet of the most
frequently occurring ACPA fine specificities (that is,
anti-CEP-1, −Fibß36-52 and – Fil307-324) in anti-CarP
positive patients (24 months; (ß = 4.25, 95% CI 0.70 to
7.80, P = 0.019). However, when stratified for these three
ACPA specificities separately there were differences be-
tween them. The presence of anti-CarP antibodies was
associated with a higher Larsen score in anti-Fibß36-52
and anti-CEP-1 antibody positive patients at baseline,
and after 24 months, whilst more radiological damage
was found in anti-CarP positive and anti-Fil307-324 anti-
body negative patients (data not shown). The presence
of anti-CCP2 antibodies as well as antibodies against
CEP-1, Vim60-75 and CCP1/Fil307-324 was also signifi-
cantly associated with radiological findings at 24 months
and with radiological progression versus being negative,
although to a lower extent compared with analysis
for anti-CarP antibodies (data not shown). None of the
relationships of anti-CCP2, antibodies against CEP-1,
Vim60-75 and Fil307-324 remained significant in separ-
ate univariate analyses of variance including anti-CarP
antibodies that were significantly associated in all analyses
(data not shown). Adding the information on positivity for
anti-CCP2 antibodies to the presence of anti-CarP anti-
bodies further increased the association to radiological
findings at 24 months (ß = 5.4, 95% CI 2.01 to 8.78) and
for radiological progression (ß = 3.05. 95% CI 0.75 to 5.35).
Discussion
In this relatively large collection of samples from indi-
viduals before they had any symptoms of a subsequent
joint disease, increased levels of anti-CarP antibodies
were found. The levels were also further increased when
these individuals had developed RA. The levels of anti-
CarP antibodies correlated with the levels of most of the
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fore and after disease development. These findings are
consistent with previous findings but now also include
several ACPA specificities [15].
The time point for the first antibody to be detectable in
samples from the pre-symptomatic individuals was com-
parable for the anti-CarP antibodies and the different
ACPA specificities and to anti-CCP2 antibodies. There
was a gradual increase in the frequency of positivity for
the anti-CarP antibodies during the time pre-dating that
peaked at the onset of symptoms. The frequency of these
antibodies was lower than the three most frequently oc-
curring ACPA fine specificities (anti-CEP-1, −Fibß36-52
and –Fil307-324 peptides), and also than anti-CCP2 anti-
bodies during the pre-dating period. However, analyses of
samples closer to symptom onset showed that the fre-
quency of anti-CarP antibodies almost reached the level of
Fil307-324 peptide antibodies.
In our previous study we found a clear and significant
increase during the predating time of antibodies against
CEP-1, Fibß36-52 and Fil307-324 peptide and also of
anti-CCP2 antibodies [7]. Antibodies against Vim60-75
increased shortly before the disease developed. The
increasing frequency of anti-CarP antibodies initially ap-
peared to be more similar to antibodies against Vim60-75
but shortly before the onset of symptoms more closely
reached the level of antibodies against Fil307-324 peptide.
Even though in our study 3% of the RA patients are
single positive for anti-CarP antibodies and 36% are sin-
gle positive for anti-CCP there is also a substantial por-
tion of patients (39%) who are double positive and,
therefore, cross-reactivity towards citrullinated and car-
bamylated proteins must be considered. Previous experi-
ments indicated that, next to cross-reactive antibodies,
antibodies only reacting with either citrullinated or car-
bamylated proteins were also present in RA [20]. In
addition results from a recent study by Jiang et al. [21] on
two large cohorts of RA found similar distributions re-
garding anti-CarP and anti-CCP antibodies and also found
completely different HLA associations for anti-CarP and
anti-CCP antibodies. In addition, the association between
anti-CCP antibodies and smoking was not found for anti-
CarP antibodies. Collectively, these findings do not favour
the idea that anti-CarP antibodies only represent cross-
reactivity to citrullinated antigen. It is likely that both
cross-reactive and non-cross-reactive antibodies co-exist.
Our results on the appearance of anti-CarP antibodies
in samples collected years before the onset of symptoms
confirm previous observations [14], although the num-
ber of samples available for this study is larger and not
restricted to those individuals identified as being positive
in their last sample before being diagnosed with RA.
Our cohort is only restricted to samples donated less
than 13 years before onset of symptoms. Anti-CarPantibodies were strongly associated with RA both among
the pre-symptomatic individuals and among RA-patients
(OR = 7.1 and 23.2, respectively). However, when ad-
justed for the presence of anti-CCP2, the association
was non-significant (OR = 2.4 95% CI 0.9 to 6.7) in the
pre-symptomatic individuals but still significant in RA
patients (OR = 3.8 95% CI 1.2 to 12.2). However, after
stratification for anti-CCP2 antibodies the association of
anti-CarP antibodies and disease development remained
significant in anti-CCP2 negative individuals irrespective
of adjustments for each separate ACPA fine specificities
or analysed as one group. Anti-CarP antibodies were as-
sociated with disease development when adjusted for all
of the ACPA fine specificities, each analysed separately
or in combination as one group with anti-CCP2 anti-
bodies. Only 3% of the pre-symptomatic individuals and
RA patients, respectively, were anti-CarP positive anti-
CCP2 negative when the group of individuals before
symptom onset or of RA patients were analysed. How-
ever, we found that if we only considered a group of
anti-CCP2 negative patients, the frequency of anti-CarP
positive antibodies was 10.4%. This information could be
useful in a clinical situation to diagnose an arthritis as
RA when the anti-CCP2 test is negative.
The present cohort provided the opportunity to evalu-
ate the radiological findings when the symptoms had de-
veloped and the individuals were diagnosed with RA and
at a follow-up after 24 months. We found that the pres-
ence of anti-CarP antibodies before onset of symptoms
of the disease predicted the radiological findings at base-
line. Furthermore, we were able to confirm the findings
by Shi and colleagues [13] that the presence of anti-CarP
antibodies is associated with the rate of radiological de-
struction. In the present study this was already apparent
at baseline, after 24 months and also calculated as the
change over time. The association of anti-CarP antibody
positivity was particularly evident in anti-CCP2 negative
or Fil307-324 peptide negative individuals. The associa-
tions of anti-CCP2, and some of the ACPA specificities
(CEP-1, Vim60-75 and Fil307-324) were also associated
with radiological findings at 24 months and with the
change over time but they did not remain significant
after adjusting for presence of anti-CarP antibodies.
Conclusions
We conclude that the anti-CarP antibodies are present
years before the onset of symptoms of RA. These anti-
bodies are also associated with disease development after
adjusting for the presence of different ACPA fine speci-
ficities and in anti-CCP2 negative individuals. We are
also able to confirm that the presence of these antibodies
is related to radiological destruction at diagnosis and to
the radiological progression observed once the disease
has developed.
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